10 November 2017
EMA/PDCO/738440/2017
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 7-10 November 2017

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

7 November 2017, 14:00- 19:00, room 3A

8 November 2017, 08:30- 19:00, room 3A

9 November 2017, 08:30- 19:00, room 3A

10 November 2017, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted with amendments.

1.3. Adoption of the minutes

The minutes of the October 2017 PDCO plenary meeting were adopted with amendments and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Brazikumab - EMEA-001929-PIP01-16

Allergan Limited; Crohn's disease, Ulcerative colitis

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

A positive opinion was adopted on D120.

2.1.2. Susoctocog alfa - EMEA-000753-PIP02-16

Baxalta Innovations GmbH; Congenital haemophilia A with antibodies (inhibitors) to human factor VIII / Peri-operative management in patients with congenital haemophilia A with antibodies (inhibitors) to human FVIII

Day 120 opinion

Haematology-Hemostaseology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's responses to D90 outstanding issues and therefore a positive opinion was adopted.

2.1.3. Risankizumab - EMEA-001776-PIP02-17

AbbVie Ltd; Chronic Idiopathic Arthritis

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 90 discussion. Moreover, the committee received clarification which was deemed agreeable. A positive opinion was adopted.

2.1.4. Trazodone hydrochloride - EMEA-002142-PIP01-17

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A; Treatment of insomnia

Day 120 opinion

Neurology

Summary of committee discussion:

The Committee re-discussed the application including the additional information received since Day 90 and concluded that all issues have now been resolved, the PIP is approvable. A positive opinion was adopted.

2.1.5. Carotuximab - Orphan - EMEA-002138-PIP01-17

TRACON Pharma Limited; Treatment of soft tissue sarcoma

Day 120 opinion

Oncology

Summary of committee discussion:

Following the Day 30 discussion a draft opinion was shared with the applicant and an agreement was reached on the last few outstanding issues.
Thus, the PDCO adopted a positive opinion on the paediatric plan proposed by the applicant.

2.1.6. fully human monoclonal antibody (mAb) directed against the human PD-1 receptor - EMEA-002007-PIP02-17

Regeneron Ireland U.C.; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) / Treatment of newly diagnosed diffuse intrinsic pontine gliomas (DIPG), newly diagnosed and recurrent high-grade gliomas (HGG)

Day 120 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the application for cemiplimab also taking into account the clarifications received after D90 and the applicant's comments on the draft opinion.

In conclusion, the PDCO recommends granting a paediatric investigation plan for cemiplimab for the entire paediatric population (from birth to less than 18 years of age) and a deferral.

2.1.7. Vosoritide - Orphan - EMEA-002033-PIP01-16

BioMarin International Limited; Treatment of achondroplasia

Day 120 opinion

Other

Summary of committee discussion:

Considering the new information received after day 90 all issues are resolved.
Taking the above into account a positive opinion endorsing the PIP has been adopted.

2.1.8. Formoterol fumarate / glycopyrronium bromide / budesonide - EMEA-002063-PIP01-16

Pearl Therapeutics, Inc.; Asthma / For the regular treatment of asthma in children 6 to 11 years of age where use of a triple combination medicinal product (ICS, LAMA and LABA) is appropriate: • patients not adequately controlled with ICS and another controller such as a LABA or LAMA

Day 120 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO discussed this procedure on D120. The applicant's responses to the D90 issues were acknowledged. All issues were resolved and a positive opinion was adopted.

2.1.9. Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene - EMEA-002224-PIP01-17

Quark Pharmaceuticals, Inc.; Treatment of optic nerve bleeding and vascular disorders / Treatment of ischaemic optic neuropathy

Day 60 opinion

Ophthalmology

Summary of committee discussion:

A positive opinion was adopted on D60.
Based on the assessment of this application and discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of optic ischaemic neuropathy.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.10. Sirolimus - Orphan - EMEA-002213-PIP01-17

Vascular Therapies, Inc.; Prevention of arteriovenous access dysfunction

Day 60 opinion

Other

Summary of committee discussion:

The PDCO confirmed the outcome of the discussion of Day 30 and agreed with a full waiver based on lack of significant therapeutic benefit for all paediatric age groups in the condition "prevention of arteriovenous access dysfunction".
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Sirolimus for all subsets of the paediatric population (0 to less than 18 years of age) in the condition of Prevention of arteriovenous access dysfunction.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Fingolimod (hydrochloride) - EMEA-C-000087-PIP01-07-M05

Novartis Europharm Limited; Treatment of Multiple Sclerosis

Day 30 opinion

Neurology

Summary of committee discussion:

The PDCO adopted on 10 November 2017 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0050/2017) of 03 April 2017.

2.2.2. L-Asparaginase encapsulated in Erythrocytes - EMEA-C2-000341-PIP02-09-M04

ERYTECH Pharma S.A.; Treatment of Acute Lymphoblastic Leukaemia

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO discussed the compliance check for the completed Study.
The PDCO therefore concluded that Study was not compliant with the latest Agency's Decision (P/0267/2017) of 4 September 2017.

2.2.3. Cytarabine (liposomal combination) / Daunorubicin (liposomal combination) - EMEA-C1-001858-PIP02-16-M01

Jazz Pharmaceuticals Ireland Limited; Treatment of acute myeloid leukaemia

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO discussed the compliance request on 10 November 2017.
The PDCO confirmed that the studies were compliant with the latest Agency's Decision (P/0299/2017) of 04 October 2017.

The PDCO finalised on 10 November 2017 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.4. Recombinant human nerve growth factor - EMEA-C-001729-PIP01-14-M01

Dompé farmaceutici SpA; Treatment of neurotrophic keratitis

Day 30 Opinion

Ophthalmology

Summary of committee discussion:

The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision. The PDCO adopted an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision.

2.2.5. Avacopan - EMEA-C1-002023-PIP01-16-M01

ChemoCentryx, Ltd.; Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Day 60 letter

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO discussed the completed Studies and considered that these are not compliant with the latest Agency's Decision (P/0268/2017) of 7 September 2017.
The PDCO finalised on 8 November 2017 this partially completed compliance procedure.

2.2.6. Mepolizumab - EMEA-C-000069-PIP02-10-M08

GSK TRADING SERVICES LIMITED; Treatment of asthma

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO took note of preceding procedures and reports on partially completed compliance (EMEA-C1-000069-PIP02-10-M02 and EMEA-C2-000069-PIP02-10-M04).
The PDCO adopted on 10 November 2017 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0239/2017) of 11 August 2017.

2.2.7. Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/<Official Strain>(H1N1), A/<Official Strain>(H3N2), B/<Official Strain>Yamagata lineage, B/<Official Strain>Victoria lineage based on annual recommendations by WHO, CHMP (EU) and other regional or local authorities - EMEA-C1-001782-PIP01-15

Abbott Biologicals B.V.; Prevention of influenza infection

Day 30 letter

Vaccines

Summary of committee discussion:

The completed study was checked for compliance

The PDCO discussed the completed study and considered that this is not compliant with the latest Agency's Decision (P/0182/2015) of 07 August 2015.

2.2.8. Galcanezumab - EMEA-C3-001860-PIP03-16 – POSTPONED TO DECEMBER

Eli Lilly Nederland B.V.; Prevention of migraine headaches

Day 1 letter

Neurology

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Recombinant human glutamic acid decarboxylase (rhGAD65) - EMEA-000609-PIP01-09-M01

Diamyd Medical AB; E10 Insulin-dependent diabetes mellitus / Treatment of type 1 Diabetes Mellitus of recent onset

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The Applicant has submitted answers to the questions forwarded by the PDCO.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, and the answers to the questions submitted, the PDCO considered that the proposed changes cannot be accepted.
The PDCO therefore adopted a negative Opinion on the request of modification of the agreed PIP as set in the Agency's latest decision (P/167/2010).

2.3.2. Eluxadoline - EMEA-001579-PIP01-13-M02

Allergan Limited; Irritable bowel syndrome with diarrhoea

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO discussed this procedure on D60.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0021/2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Human coagulation factor X - Orphan - EMEA-000971-PIP01-10-M03

Bio Products Laboratory Limited; Treatment of hereditary factor X deficiency

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0188/2014 of 06 August 2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Avacopan - Orphan - EMEA-002023-PIP01-16-M02

ChemoCentryx, Ltd.; Treatment of ANCA-associated vasculitis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0268/2017 of 7 September 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Human normal immunoglobulin for subcutaneous administration - EMEA-001853-PIP01-15-M01

Grifols Therapeutics Inc; Treatment for primary immunodeficiency

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0111/2016 of 15 April 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Bezlotoxumab - EMEA-001645-PIP01-14-M02

Merck Sharp & Dohme (Europe), Inc.; Treatment of Clostridium difficile infection / indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in paediatric patients at high risk for recurrence of CDI

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The applicant provided further clarifications, which were deemed acceptable. Otherwise the committee confirmed the outcome of the Day 30 discussion.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0340/2014 of 22/12/2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Ataluren - Orphan - EMEA-000115-PIP01-07-M09

PTC Therapeutics International, Limited; Treatment of dystrophinopathy ICD-10: G71.0 Muscular dystrophy [of Duchenne and Becker] / Treatment of nonsense-mutation dystrophinopathy

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO's views expressed on day 30 were re-discussed and endorsed. The re-discussion also took into account the applicant's clarifications and supplementary information submitted between day 30 and day 60.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP

as set in the Agency's latest decision (P/0283/2016 of 4 November 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M04

GW Pharma Ltd; Spasticity / Intractable spasticity due to cerebral palsy or traumatic CNS injury

Day 60 opinion

Neurology

Summary of committee discussion:

As foreseen by the Day 30 conclusion, the PDCO adopted a negative opinion.

2.3.9. Blinatumomab - Orphan - EMEA-000574-PIP02-12-M02

Amgen Europe B.V.; Treatment of Acute Lymphoblastic Leukaemia / Treatment of Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) in patients 1 month and older.

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed the applicant's request for modification for blinatumomab for the second time during its plenary on 10 November 2017. As already discussed during their day 30 discussion in October 2017, the PDCO considered that the proposed changes seemed acceptable
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0014/2016 of 29/01/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Ibrutinib - Orphan - EMEA-001397-PIP03-14-M03

Janssen-Cilag International N.V.; Treatment of mature B-cell neoplasms / Treatment of children from 1 year to less than 18 years of age with newly-diagnosed and relapsed/refractory mature B-cell lymphoma, that is, diffuse large B-cell lymphoma or Burkitt and Burkitt-like lymphoma.

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the proposed modification also taking into account the clarifications provided by the applicant after the D30 discussion.
All the issues were considered solved.

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0100/2017 of 11 April 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Inotuzumb ozogamicin - Orphan - EMEA-001429-PIP01-13-M02

Pfizer Ltd; Treatment of Acute Lymphoblastic Leukaemia / For the treatment of relapsed or refractory B cell precursor Acute Lymphoblastic Leukaemia

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO accepted the modifications proposed by the applicant.

2.3.12. Human Thrombin / Human Fibrinogen - EMEA-001149-PIP01-11-M04

Omrix Biopharmaceuticals N.V.; Treatment of cerebrospinal fluid leakage resulting from a surgical procedure, Treatment of haemorrhage resulting from a surgical procedure / indicated for suture line sealing in dura mater closure., indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis., indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis.

Day 60 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0067/2016 of 18 March 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Lanadelumab - Orphan - EMEA-001864-PIP01-15-M01

Shire Pharmaceuticals Ireland Limited; Treatment of hereditary angioedema

Day 60 opinion

Other

Summary of committee discussion:

The PDCO discussed the applicant's request for modification for Lanadelumab and the additional clarifications provided. All outstanding issues have been addressed satisfactorily.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0273/2016 of 05/10/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Sildenafil - Orphan - EMEA-000671-PIP01-09-M09

Pfizer Limited; Treatment of Pulmonary Arterial Hypertension (PAH)

Day 60 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes to the timelines could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0092/2015 of 8 May 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.15. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each - EMEA-000794-PIP01-09-M01

LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family)

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO's views expressed on day 30 were re-discussed and endorsed.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision of 26 November 2010.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50) - EMEA-000792-PIP01-09-M01

LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family)

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO's views expressed on day 30 were re-discussed and endorsed.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision of 26 November 2010.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen - EMEA-000795-PIP01-09-M01

LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family)

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO's views expressed on day 30 were re-discussed and endorsed.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision of 26 November 2010.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

2.4.1. Crisaborole - EMEA-002065-PIP01-16

Pfizer Ltd; Mild to moderate atopic dermatitis

Day 30 opinion

Dermatology

Summary of committee discussion:

The Opinion was adopted via a written procedure on 31 October 2017.

In conclusion, the PDCO maintains its opinion.

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Chloroprocaine Hydrochloride - EMEA-000639-PIP03-16

Peripheral nerve block (local anesthesia by perineural injection)

Day 90 discussion

Anaesthesiology

3.1.2. Lucerastat - Orphan - EMEA-002095-PIP01-16

Idorsia Pharmaceuticals Deutschland GmbH; Treatment of Fabry disease

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.3. EMEA-002109-PIP01-16

K75.8 Other specified inflammatory liver diseases (non-alcoholic steatohepatitis [NASH]) / Treatment of Non-Alcoholic Steatohepatitis (NASH) with mild to severe fibrosis (F1-F4) in paediatric subjects, 8 to < 18 years of age

Day 90 discussion

Gastroenterology-Hepatology

3.1.4. Maralixibat Chloride - Orphan - EMEA-001475-PIP03-17

Shire Pharmaceuticals Ireland Limited; Treatment of Progressive Familial Intrahepatic Cholestasis

Day 90 discussion

Gastroenterology-Hepatology

3.1.5. Glutamine (Levoglutamide) - Orphan - EMEA-001996-PIP02-16

Emmaus Medical Europe Ltd.; Sickle cell disease / Glutamine (Levoglutamide) is indicated for the prevention of sickle cell crises in adults and children older than 5 years suffering from Sickle Cell Disease.

Day 90 discussion

Haematology-Hemostaseology

3.1.6. Upadacitinib - EMEA-001741-PIP02-16

Treatment of Uclerative Colitis

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.7. Obiltoxaximab - EMEA-002144-PIP01-17

Treatment of bacillary infection, Prevention of bacillary infection / Treatment of inhalation anthrax following exposure to Bacillus anthracis in combination with appropriate antibacterial drugs, Post-exposure prophylaxis of inhalation anthrax when alternative therapies are not available or are not appropriate

Day 90 discussion

Infectious Diseases

3.1.8. Gilteritinib (as fumarate) - EMEA-002064-PIP01-16

Treatment of acute myeloid leukemia / Treatment of FLT3/ITD positive acute myeloid leukemia

Day 90 discussion

Oncology / Haematology-Hemostaseology

3.1.9. Recombinant Clostridium difficile Toxoid B / Recombinant Clostridium difficile Toxoid A - EMEA-002112-PIP01-16

Prevention of Clostridium difficile infection (CDI) / Active immunization for the prevention of primary Clostridium difficile infection in children and adolescents 2 to 18 years of age

Day 90 discussion

Vaccines

3.1.10. EMEA-001527-PIP02-17

Treatment of obesity

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.11. Itacitinib - EMEA-002178-PIP01-17

Treatment of acute Graft versus Host Disease (D89.810, ICD-10-CM) / Treatment of steroid naïve paediatric population with acute graft versus host disease after allogeneic hematopoietic stem cell transplantation

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.12. Fremanezumab - EMEA-001877-PIP03-17

Prevention of cluster headache

Day 60 discussion

Neurology

3.1.13. Setmelanotide - Orphan - EMEA-002209-PIP01-17

Rhythm Pharmaceuticals, Inc; Treatment of appetite and general nutrition disorders / Treatment of obesity and/or hyperphagia associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway

Day 60 discussion

Nutrition

3.1.14. Afatinib - EMEA-001596-PIP02-17

Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma, Treatment of paediatric patients with tumours with known ErbB deregulations irrespective of tumour histology, Treatment of lung carcinoma, Treatment of urether and bladder carcinoma / Treatment of paediatric patients aged between ≥ 1 year and ≤ 18 years with recurrent or refractory tumours with known ErbB deregulation and irrespective of tumour histology.

Day 60 discussion

Oncology

3.1.15. Fosnetupitant / palonosetron - EMEA-001198-PIP03-17

Prevention of Chemotherapy-Induced Nausea and Vomiting

Day 60 discussion

Other

3.1.16. EMEA-002160-PIP01-17

Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age

Day 60 discussion

Vaccines / Infectious Diseases

3.1.17. Clade C gp140 - EMEA-002221-PIP01-17

Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age

Day 60 discussion

Vaccines / Infectious Diseases

3.1.18. Mosaic gp140 / Clade C gp140 - EMEA-002161-PIP01-17

Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age

Day 60 discussion

Vaccines / Infectious Diseases

3.1.19. Rosuvastatin calcium / Acetylsalicylic acid - EMEA-002239-PIP01-17

Prevention of cardiovascular events

Day 30 discussion

Cardiovascular Diseases

3.1.20. Baricitinib - EMEA-001220-PIP03-16

Treatment of atopic dermatitis / Treatment of patients with moderate to severe atopic dermatitis

Day 30 discussion

Dermatology

3.1.21. Fluorocholine (18F) - EMEA-002129-PIP02-17

Visualisation of choline metabolism in malignant neoplasms

Day 30 discussion

Diagnostic

3.1.22. Bis-choline tetrathiomolybdate - Orphan - EMEA-002232-PIP01-17

Wilson Therapeutics AB; Treatment of Wilson disease

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.23. Ethinyl estradiol / Dienogest - EMEA-002229-PIP01-17

Contraception / Oral contraception

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.24. Semaglutide - EMEA-001441-PIP03-17

Treatment of obesity

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.25. Orphan - EMEA-002233-PIP01-17

Zealand Pharma A/S; Treatment of hypoglycaemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.26. Amiselimod - EMEA-002227-PIP01-17

Ulcerative colitis / Treatment of moderately to severely active UC in children and adolescents who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy, a TNF-alpha antagonist, or an integrin inhibitor.

Day 30 discussion

Gastroenterology-Hepatology

3.1.27. Ustekinumab - EMEA-000311-PIP05-17

Treatment of Ulcerative Colitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.28. (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid - Orphan - EMEA-002069-PIP02-17

Corbus Pharmaceuticals Holdings Inc; Treatment of systemic sclerosis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.29. Riociguat - Orphan - EMEA-000718-PIP03-17

Bayer AG; Treatment of Systemic Sclerosis / Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.30. The whole range of unmanipulated autologous mononuclear cells derived from human umbilical cord blood (Hau-UCB-mnc) - Orphan - EMEA-001799-PIP02-17

BrainRepair UG (haftungsbeschränkt); Periventriculaleukomalacia (PVL) ICD-10-CM P91.2

Day 30 discussion

Neonatology - Paediatric Intensive Care

3.1.31. Vatiquinone - Orphan - EMEA-002235-PIP01-17

Edison Orphan Pharma BV; RARS2 syndrome (ICD10 code G31.9)

Day 30 discussion

Neurology

3.1.32. Tucatinib - EMEA-002242-PIP01-17

Treatment of breast malignant neoplasms

Day 30 discussion

Oncology

3.1.33. Recombinant human epidermal growth factor - EMEA-002258-PIP01-17

Diabetic foot ulcer

Day 30 discussion

Other / Endocrinology-Gynaecology-Fertility-Metabolism

3.1.34. Human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with Tat-MYC fusion protein - Orphan - EMEA-002185-PIP02-17

Taiga Biotechnologies, Inc.; Severe Combined Immunodeficiency

Day 30 discussion

Other / Immunology-Rheumatology-Transplantation

3.1.35. Purified Rabies virus - EMEA-002234-PIP01-17

Prevention of rabies disease, treatment of exposure to rabies virus

Day 30 discussion

Vaccines

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Clostridium Botulinum neurotoxin type A (150 kD) - EMEA-C-001039-PIP01-10-M02

Merz Pharmaceuticals GmbH; Treatment of muscle spasticity

Day 30 discussion

Neurology

3.2.2. Clostridium Botulinum neurotoxin type A (150 kD) - EMEA-C1-001039-PIP02-12-M02

Merz Pharmaceuticals GmbH; Treatment of sialorrhea

Day 30 discussion

Neurology

3.2.3. Japanese-encephalitis virus, inactivated - EMEA-C-000559-PIP01-09-M04

Valneva Austria GmbH; Prevention of Japanese encephalitis

Day 30 discussion

Vaccines

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Regadenoson - EMEA-000410-PIP01-08-M02

Rapidscan Pharma Solutions EU Limited; Myocardial perfusion disturbances / Diagnostic evaluation of myocardial perfusion disturbances

Day 30 discussion

Cardiovascular Diseases

3.3.2. Gadolinium,[α3,α6,α9-tris[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-3-oxopropyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-κN3,κN6,κN9,κN15,κO3,κO6,κO9] - EMEA-001949-PIP01-16-M01

GUERBET; Detection and visualization of areas with disruption of the blood brain barrier and/or abnormal vascularity for the central nervous system (CNS), or of any type of diseases from different body regions (soft tissues, bone and internal body structures/organs) for diagnostic purposes.

Day 30 discussion

Diagnostic

3.3.3. Empagliflozin - EMEA-000828-PIP01-09-M06

Boehringer Ingelheim International GmbH; Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Linagliptin (as base) - EMEA-000498-PIP01-08-M07

Boehringer Ingelheim International GmbH; Type 2 Diabetes Mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Sitagliptin phosphate - EMEA-000470-PIP01-08-M10

Merck Sharp and Dohme (Europe), Inc.; Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Baricitinib - EMEA-001220-PIP01-11-M02

Eli Lilly and Company Limited; Treatment of chronic idiopathic arthritis (including

rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis, Treatment of JIA-associated uveitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.7. Human normal immunoglobulin - EMEA-001797-PIP01-15-M01

Octapharma Pharmazeutika Produktionsges.m.b.H; Primary Immunodeficiency Diseases

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.8. Ixekizumab - EMEA-001050-PIP01-10-M03

Eli Lilly & Company Limited; Plaque psoriasis, Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Children with juvenile idiopathic arthritis subtypes of enthesitis-related arthritis (including JoAS) and juvenile psoriatic arthritis., Treatment of severe chronic plaque psoriasis in paediatric patients from the age of 6 years who are not adequately controlled by topical therapies.

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.9. Tofacitinib - EMEA-000576-PIP01-09-M08

Pfizer Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis) / Juvenile Idiopathic arthritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.10. Ustekinumab - EMEA-000311-PIP03-11-M03

Janssen-Cilag International NV; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, PsA and juvenile idiopathic arthritis [JIA])

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.11. Ceftaroline fosamil - EMEA-000769-PIP01-09-M07

Pfizer Limited; Treatment of cSSTI (complicated skin and soft tissue infections) / Treatment of CAP (community-aquired pneumonia)

Day 30 discussion

Infectious Diseases

3.3.12. Cobicistat / atazanavir sulphate - EMEA-001465-PIP01-13-M02

Bristol-Myers Squibb Pharma EEIG; Treatment of HIV-1 infection / indicated in combination with other ARV medicinal products for the treatment of HIV-1 infected adults and children from 3 years of age without known mutations associated with resistance to atazanavir.

Day 30 discussion

Infectious Diseases

3.3.13. Oseltamivir phosphate - EMEA-000365-PIP01-08-M09

Roche Registration Limited; Treatment and prevention of influenza / Treatment and prevention of influenza in healthy and immunocompromised patients from 0 to less than 18 years of age

Day 30 discussion

Infectious Diseases

3.3.14. Posaconazole - EMEA-000468-PIP02-12-M04

Merck Sharp & Dohme (Europe), Inc.; Prevention of invasive fungal infections / For treatment of invasive fungal infections in the following paediatric patients: -Invasive aspergillosis in patients with disease that is refractroy to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; Treatment of invasive aspergillosis, -Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Day 30 discussion

Infectious Diseases

3.3.15. Tedizolid phosphate - EMEA-001379-PIP01-12-M03

Merck Sharp & Dohme (Europe) Inc.; Treatment of acute bacterial skin and skin structure infections

Day 30 discussion

Infectious Diseases

3.3.16. Tenofovir alafenamide - EMEA-001584-PIP01-13-M03

Gilead Sciences International Ltd.; Treatment of chronic hepatitis B / indicated for the treatment of chronic hepatitis B infection in paediatric patients aged 2 years and above.

Day 30 discussion

Infectious Diseases

3.3.17. Lacosamide - EMEA-000402-PIP02-11-M05

UCB Pharma S.A.; Treatment of Epilepsy - Partial-onset seizures [G40.0 - G40.1 - G40.2]

Day 30 discussion

Neurology

3.3.18. Midostaurin - Orphan - EMEA-000780-PIP01-09-M04

Novartis Europharm Ltd; C92.0 Acute myeloid leukaemia, C94.3 Mast cell leukaemia, C96.2 Malignant mastocytosis / Treatment of paediatric patients with FLT3 mutated AML, newly diagnosed

Day 30 discussion

Oncology

3.3.19. Pembrolizumab - EMEA-001474-PIP02-16-M01

Merck Sharp & Dohme (Europe), Inc.; Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)., Treatment of Hodgkin Lymphoma / Treatment of advanced, untreated or previously treated, malignant melanoma in children from 12 year old to less than 18 years of age. Treatment as monotherapy of a PD-L1 positive paediatric malignant solid tumor in children from 6 months to less than 18 years of age., •Treatment of classical Hodgkin lymphoma with incomplete early response to front-linechemotherapy in children from 3 years to less than 18 years of age •Treatment of relapsed or refractory classical Hodgkin lymphoma in children from 5 years to lessthan 18 years of age

Day 30 discussion

Oncology

3.3.20. Burosumab; Human recombinant IgG1 monoclonal antibody to fibroblast growth factor 23 (FGF23); - Orphan - EMEA-001659-PIP01-15-M03

Ultragenyx Pharmaceutical Inc.; X-linked Hypophosphatemia

Day 30 discussion

Other

3.3.21. Conestat alfa - EMEA-000367-PIP01-08-M07

Pharming Group N.V.; D84.1 Defects in the complement system C1 esterase inhibitor (C1-INH) deficiency / Treatment of acute attacks of angioedema associated with hereditary C1 esterase inhibitor deficiency

Day 30 discussion

Other

3.3.22. Ivacaftor / lumacaftor - EMEA-001582-PIP01-13-M07

Vertex Pharmaceuticals (Europe) Limited; cystic fibrosis / Treatment of cystic fibrosis

Day 30 discussion

Other

3.3.23. Matrix applied characterised autologous cultured chondrocytes - EMEA-000979-PIP01-10-M02

Vericel Denmark ApS; repair of symptomatic, full-thickness cartilage defects of the knee

Day 30 discussion

Other

3.3.24. Birch pollen extract (Betula verrucosa) - EMEA-001879-PIP01-15-M01

ALK Abelló A/S; J30.1 Allergic rhinitis due to pollen / Treatment of tree pollen allergic rhinitis and/or conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.25. Reslizumab - EMEA-001202-PIP02-13-M02

Teva Pharmaceuticals Europe; Treatment of asthma / indicated as add- on treatment in adult patients with severe eosinophilic asthma

Day 30 discussion

Pneumology - Allergology

3.3.26. N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine - EMEA-001452-PIP01-13-M01

GlaxoSmithKline R & D; Treatment of anaemia associated with chronic renal disease

Day 30 discussion

Uro-nephrology / Haematology-Hemostaseology

3.3.27. Outer Membrane Vescicles (OMV) from Neisseria Meningitidis serogroup B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 / Recombinant Neisseria Meningitidis serogroup B fHbp fusion protein / Recombinant Neisseria Meningitidis serogroup B NadA protein / Recombinant Neisseria Meningitidis serogroup B NHBA fusion protein - EMEA-000139-PIP01-07-M02

GSK Vaccines S.r.l.; Prevention of meningitis

Day 30 discussion

Vaccines

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 23 January 2018 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of committee discussion:

None

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

None

7. Discussion on the inclusion of an indication within a condition in an agreed PIP / waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP / waiver

7.1.1. Rivaroxaban - EMEA-000430-PIP01-08-M10

Bayer AG; Prevention of thromboembolic events/ Prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in adult patients with Coronary Artery Disease or Peripheral Artery Disease

Summary of committee discussion:

The PDCO confirmed that the proposed indication “prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in adult patients with Coronary Artery Disease or Peripheral Artery Disease”, is considered to be covered by the condition “prevention of thromboembolic events”.

8. Annual reports on deferrals

Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. User manual on CxMP/EMA external representation

Summary of committee discussion:

The user manual describes the process for allowing a scientific committee (CxMP), working party (WP) or scientific advisory group (SAG) chair, member, alternate or expert to participate in an external meeting or conference representing the CxMP or the European Medicines Agency (EMA or Agency) in an official capacity, where the participation is fully or partially reimbursed by the Agency or by the organiser of the meeting or conference. The PDCO noted the user manual.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in

October 2017 was presented to the PDCO members.

The members were also informed about 2 medicinal products, Cubicin and Pegasys for which the CHMP adopted a positive opinion recommending a paediatric indication during their meeting in October 2017.

9.2.2. CHMP Oncology Working Party Workshop on: Histology – independent indications in Oncology

PDCO member: Koenraad Norga

Summary of committee discussion:

The PDCO was informed about the Workshop.

9.2.3. CHMP-PDCO common session

Summary of committee discussion:

The CHMP-PDCO common session took place.

9.2.4. Questions from PRAC to PDCO following a MS request for PRAC Advice

Summary of committee discussion:

The questions of the PRAC have been presented to the PDCO; volunteers to work on the draft response have been identified.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.

9.3.2. Non-clinical Working Group: Call for additional members

Summary of committee discussion:

The call for additional members to the Non-clinical Working Group has been announced to the PDCO.

9.3.3. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.3.4. Formulation Working Group: PDCO FWG participants 2018

PDCO member: Brian Aylward

Summary of committee discussion:

The PDCO adopted the list of PDCO FWG experts for the year 2018.

9.3.5. Guideline on the development of new medicinal products for the treatment of Crohn's Disease and ulcerative colitis – POSTPONED TO DECEMBER

PDCO member: Peter Szitanyi

The topic was postponed to December PDCO.

9.3.6. Guideline on the clinical evaluation of vaccines

Revised draft for comments by 14 November 2017

Summary of committee discussion:

The Committee was introduced to the scope of the revised draft guideline and invited to comment.

9.3.7. Minutes of the PCWP/HCPWP joint meeting held on 20 September 2017

The document was tabled for information.

9.3.8. FDA Public Workshop- Advancing the Development of Pediatric Therapeutics (ADEPT) Application of "Big Data" to Pediatric Safety Studies - Report from the meeting

Summary of committee discussion:

Key messages were presented arising from a recent workshop organised by the FDA entitled "Application of "Big Data" to Paediatric Safety Studies" under the umbrella of ADEPT (Advancing the Development of Paediatric Therapeutics). The workshop focussed predominantly on big data in the context of real world data (RWD).

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

Summary of committee discussion:

the coordinator of the German Neonatal Network (GNN) presented the structure, aims and current projects of the network to the PDCO. GNN, which encompasses more than 60 neonatal intensive care units in Germany and is funded by the German Federal Ministry

of Education and Research (BMBF), is a basic research network. The network started patient enrolment in 2009 and aims to enrol more than 20,000 preterm infants with a birth weight below 1500 grams over 12 years (i.e. by 2021) into an academic prospective cohort study investigating the long-term effects of genetic, clinical and social risk factors, and the influence of centre specific treatment strategies on short and long-term development of preterm neonates. The development of these infants will be followed up during a time period of six years.

The network promotes urgently needed randomised clinical trials in very low birth weight infants. The network already has and is willing to offer advice to companies on neonatal trial issues if approached e.g. in preparation of a PIP submission.

9.4.2. European Commission

10 Year report of the Paediatric regulation

Summary of committee discussion:

EC representative gave a presentation on '10 Year report of the Paediatric regulation'.

9.5. Cooperation with International Regulators

None

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

9.7.1. Draft PDCO Work plan 2018

Summary of committee discussion:

The Committee discussed the draft PDCO Work plan for 2018.

9.8. Planning and reporting

9.8.1. Report on the PDCO Strategic Review & Learning meeting in Tallinn, 4-6 October 2017

PDCO member: Irja Lutsar

Summary of committee discussion:

The Committee was provided with feedback from the PDCO Strategic Review & Learning meeting held in Tallinn on 4-6 October 2017.

10. Any other business

10.1. AOB topic

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed about the forthcoming 'paediatric strategy forum on medicine development for mature B cell malignancies in children' and on academic community's view on frontline studies in oncology PIPs.

11.1.2. Neonatology

Summary of committee discussion:

The breakout session has been cancelled.

11.1.3. Inventory

Summary of committee discussion:

The Paediatric Inventory Group convened to progress on the methodology to be used for the identification of unmet needs through the paediatric investigation plans assessed by the PDCO.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the 7 – 10 November 2017 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	EMEA-000139-PIP01-07-M02 EMEA-C-000069-PIP02-10-M08 EMEA-001452-PIP01-13-M01
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Adriana Andrić	Member	Croatia	No interests declared	
Suzana Mimica Matanovic	Alternate	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Peter Szitanyi	Alternate	Czech Republic	No interests declared	
Marianne Orholm	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Ann Marie Kaukonen	Member	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No interests declared	
Sigita Burokiene	Member	Lithuania	No interests	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Eva Agurell	Alternate	Sweden	No restrictions applicable to this meeting	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando	Member	Healthcare Professionals'	No interests	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Cabanas		Representative	declared	
Riccardo Riccardi	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Shiva Ramroop	Expert - in person*	United Kidgdom	No restrictions applicable to this meeting	
Wolfgang Göpel	Expert - in person*	Germany	No restrictions applicable to this meeting	
Sara Homer	Expert - in person*	United Kingdom	No interests declared	
Representative from the European Commission participated in the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the product(s) they have been invited to talk about.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/